HealthInvest Partners’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

HealthInvest Partners’s Portfolio KRTX Stock Details KRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$6.68K	Buy	+34	New	+$7.29K	0.01%	47

Other funds holding KRTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

HealthInvest Partners's KRTX Position: Q4 2022 in Review

HealthInvest Partners opened a new position in Karuna Therapeutics, Inc. Common Stock (KRTX) in Q4 2022: 34 shares worth $6.68K. The stake represents 0.01% of the portfolio and ranks #47 among its holdings.

248 funds tracked by Wall St. Rank hold KRTX as of Q4 2022.

HealthInvest Partners held 34 shares of Karuna Therapeutics, Inc. Common Stock worth $6.68K as of Q4 2022.
Karuna Therapeutics, Inc. Common Stock was a new HealthInvest Partners position in Q4 2022.
Karuna Therapeutics, Inc. Common Stock made up 0.01% of HealthInvest Partners's portfolio in Q4 2022, its #47 holding.
248 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q4 2022.

Based on HealthInvest Partners's 13F filing for Q4 2022, filed 14 Feb 2023.